BDA
3.5.2022 21:06:05 CEST | Business Wire | Press release
The Bermuda Business Development Agency (BDA), in partnership with the Association of Bermuda Insurers and Reinsurers (ABIR) and KBRA, is pleased to welcome climate thought leaders from around the world to Bermuda for an invite-only Bermuda Climate Summit May 23-24. The event is already at capacity, but parties interested in being added to the waitlist can email bermudaclimate@bda.bm .
The inaugural Bermuda Climate Summit will consist of an opening welcome dinner on May 23, followed by a full day of discussions on May 24, including a keynote lunch, informative panel presentations, roundtables, solutions showcase, networking opportunities, and a cocktail reception.
David Hart, BDA CEO said, “As the world’s risk capital, Bermuda is in a prime position to leverage its strengths in (re)insurance, Insurance-Linked Securities (ILS), and professional services to become the preeminent leader in climate risk finance and combat the greatest challenge of our time – climate change. Bermuda is already home to many of the world’s leading experts on weather-related catastrophes and has been working in the property catastrophe reinsurance market for decades. We are honoured to welcome global leaders to Bermuda for this extraordinary event to network, share ideas, and discuss vital solutions to the global climate crisis.”
The Hon. Walter Roban, JP, MP, Deputy Premier of Bermuda and Jim Nadler, President & CEO, KBRA will kick off proceedings by discussing Bermuda’s work in climate risk finance and how an increase in this type of financing can help mitigate against the worst effects of climate change, the benefits that innovative new technologies bring, and what a new climate finance economic pillar for Bermuda might look like.
Then John Huff, ABIR President & CEO, will moderate a panel on building resiliency in the face of climate change. Panelists include Bronwyn Claire, Senior Programme Manager, ClimateWise, Cambridge Institute for Sustainability Leadership (CISL), University of Cambridge; Ekhosuehi Iyahen, Secretary General, Insurance Development Forum; Abhisheik Dhawan, Sustainable Finance & Partnership Specialist/Corporate Lead on Climate Change, United Nations Capital Developments Fund (UNCDF); and Steven E Seitz, Director, Federal Insurance Office US Department of the Treasury.
Additional sessions will feature discussions about applied technology innovations to discuss the scale and nature of our current and anticipated climate challenges, an executive-level discussion on the growing importance of ESG and its intersection with (re)insurance and investing, and how the development of specialty financing products within the (re)insurance industry can help address climate change amid increasing consumer and regulatory pressure for climate risk management.
Guests will stay at the exclusive Rosewood Bermuda located on the shimmering waters of Bermuda’s Castle Harbour. They and their families can stay for the Bermuda Day holiday weekend to enjoy the luxury facilities and Bermuda’s many amenities including walking nature tours, twizzy tours, golf, deep-sea fishing, cave adventures, a VIP Bermuda Institute of Ocean Sciences (BIOS) tour, or a Nonsuch Island expedition. Click here to visit the BDA website for special rates and hotel information, including at the Hamilton Princess & Beach Club, conveniently located near the city of Hamilton.
The BDA thanks sponsors of Bermuda Climate Summit for their commitment to Bermuda. These include:
Partner level sponsors
- ABIR
- KBRA
Platinum sponsor
- Conduit Re
Gold sponsor
- Belco
Silver sponsor
- Aspen Re
Lanyard sponsor
- AXA XL
Beverage station sponsor
- Deloitte
Bronze sponsors
- Nephila
- HSBC Bermuda
Supporting sponsors
- Elbow Beach Capital
- Hub Culture
- KPMG
Media partner
- Bermuda Re + ILS
Click here to learn more about the BDA.
CONNECTING BUSINESS
The BDA encourages direct investment and helps companies start up, re-locate or expand their operations in our premier jurisdiction. An independent, public-private partnership, we connect you to industry professionals, regulatory officials, and key contacts in the Bermuda government to assist domicile decisions. Our goal? To make doing business in Bermuda smooth and beneficial.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503006192/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
REPLY: The Board of Directors Approves the Quarterly Report Dated 31 March 202615.5.2026 13:38:00 CEST | Press release
All economic and financial indicators grew:Consolidated revenues of €645.0 million (€607.5 million in 2025);EBITDA of €112.0 million (€105.3 million in 2025);EBIT of €95.1 million (€88.7 million in 2025);Profit before tax amounts to €99.8 million (€86.9 million in 2025). Today, the Board of Directors of Reply S.p.A. [EXM, STAR: REY] approved the results as at 31 March 2026. Since the beginning of the year, the Group has recorded a consolidated revenues amounting to €645.0 million, an increase of 6.2% compared to the corresponding data for 2025. All indicators are positive for the period. In the first quarter of 2026 the consolidated EBITDA stood at €112.0 million compared to €105.3 million in 2025, equal to 17.4% of the turnover. EBIT, from January to March, was €95.1 million (€88.7 million in 2025) and is equal to 14.7% of the turnover. The profit before tax, from January to March, was €99.8 million (€86.9 million in 2025), equal to 15.5% of the turnover. The net financial position of
Organon to Present New Research on Access and Value at ISPOR 202615.5.2026 13:30:00 CEST | Press release
New findings will highlight contraception affordability, biosimilar adoption, and access-focused analyses across the women’s health and general medicines portfolio Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present data across women’s health, biosimilars, dermatology, and neurology at ISPOR 2026, the leading global scientific conference hosted by the International Society for Pharmacoeconomics and Outcomes Research. The conference, focused on health economics and outcomes research, will take place May 17-20, 2026, in Philadelphia, Pennsylvania. Across 8 accepted abstracts, the data reflect Organon’s commitment to generating real-world evidence—rooted in lived experiences—that can help inform healthcare decision-making and improve health outcomes across a range of therapeutic areas. “Health economics and outcomes research is critical to ensuring the right treatments reach patients and that
SES Announces Extraordinary General Meeting of Shareholders15.5.2026 08:30:00 CEST | Press release
SES: Société Anonyme RCS Luxembourg B 81267 Notice is hereby given of the Extraordinary General Meeting of SES, Société Anonyme, to be held at the Company's registered office at Château de Betzdorf, L-6815 Betzdorf (the "Company"), Luxembourg, on Wednesday 17 June 2026 at 3:00 p.m. CET AGENDA Attendance list, quorum and adoption of the agenda Nomination of a secretary and of two scrutineers Cancellation of shares purchased in connection with the buy-back programme of 2 November 2023, as amended on 2 May 2024, in accordance therewith and pursuant thereto - Reduction of the share capital in accordance with article 450-5 of the law of 10 August 1915 on commercial companies, as amended, by forty-four million nine hundred ten thousand seven hundred eighty euro (EUR 44,910,780) through the cancellation of thirty-five million nine hundred and twenty-eight thousand six hundred and twenty-four (35,928,624) shares divided into (i) twenty-three million nine hundred and fifty-two thousand four hun
Experian Partners With ServiceNow to Scale Trusted Decisioning to Agentic AI15.5.2026 08:00:00 CEST | Press release
New global long‑term partnership embeds Experian’s Ascend capabilities directly into ServiceNow workflows, transforming client operations Experian, the global data and technology company, and ServiceNow (NYSE: NOW), the AI control tower for business reinvention, today unveil a new global multi-year partnership which harnesses the power of autonomous AI agents across platforms, helping businesses make faster and smarter decisions at scale. Through this partnership, autonomous AI agents can gain the ability to act faster, and more consistently, starting with employee onboarding, third-party risk management and model life cycle governance use cases. A major challenge for global organisations adopting agentic AI is achieving scale, with deployments often constrained by a lack of trusted data. In fact, industry research shows that data limitations are the primary barrier for eight in ten organisations. By connecting trusted intelligence directly into enterprise workflows, this partnership e
Meiji Seika Pharma: Positive Results from the Phase III Integral-1 Trial of Nacubactam, a Novel β-Lactamase Inhibitor, in Complicated Urinary Tract Infections or Acute Uncomplicated Pyelonephritis ― Published in The Lancet15.5.2026 03:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of two global Phase III clinical trials evaluating the efficacy and safety of its novel β-lactamase inhibitor nacubactam (development code: OP0595), have been published in The Lancet. The article is entitled “---Efficacy and safety of cefepime–nacubactam and aztreonam–nacubactam compared with imipenem–cilastatin for complicated urinary tract infection or acute uncomplicated pyelonephritis (Integral-1): a double-blind, randomised phase 3 trial” (https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)00596-9/fulltext) Integral-1 is a global, double-blind, randomized Phase III trial (jRCT2031230075) in patients with complicated urinary tract infection or acute uncomplicated pyelonephritis that compared the efficacy and safety of nacubactam co-administered with either cefepime or aztreonam versus imipenem-c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom